Merck Reports Phase 3 KEYNOTE-966 Results for Keytruda in Biliary Tract Cancer

Merck today announced results from the Phase 3 KEYNOTE-966 trial evaluating Keytruda (pembrolizumab) plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated locally advanced or metastatic biliary tract cancer. The trial met its primary endpoint, demonstrating a significant improvement in overall survival with Keytruda.